$SPR
Spirit AeroSystems Holdings Inc. Class A
PRICE
$38.62 ▼-0.387%
Extented Hours
VOLUME
2,580,705
DAY RANGE
38.27 - 40.26
52 WEEK
17.14 - 70.33
Echofin Members Consensus
coretraderuk #CoreTrader Join team
(ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Further, it has various seed programs under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Related News
-
Spirit Aerosystems PAC suspending campaign donations, Koch to evaluate future support in wake of US Capitol attack | News Break
13 Jan 2021, 15:32 -
FXNEWS24 |What Is Driving The Rally In Spirit Aerosystems Stock? | UK Forex Reviews
12 Jan 2021, 09:39 -
Cowen & Co. Stick to Their Buy Rating for Spirit Aerosystems Holdings
28 Dec 2020, 09:03 -
JPMorgan unveils its 50 'most compelling' stock picks to buy for 2021 — and details why each one will be a top performer
13 Dec 2020, 13:03 -
UBS Upgrades Boeing, Spirit AeroSystems, Doubles Price Targets
07 Dec 2020, 18:34